Chinese Hepalink acquired US Cytovance Biologics for $205 million
Shenzhen Hepalink, a Chinese provider of material to global pharma firms, has acquired Cytovance Biologics, a US Oklahoma City bio-pharma manufacturing firm, for $205 million
Established in 2003 and based in US Oklahoma City, Cytovance Biologics is a biopharmaceutical contract manufacturing company, specializing in the production of therapeutic proteins and antibodies. Established in 1998 and listed on the Shenzhen Stock Exchange, Hepalink is a provider of Heparin Sodium API to pharmaceutical companies, such as Sanofi-Aventis, Fresenius -Kabi and Novartis.
To see a list of investors from China similar to Shenzhen Hepalink, check the Chinese Investors Directory.
More details follows:
September 16, 2015 |
Filed under Chinese Healthcare Investors
Previous Post: China JD Capital acquired Ageas Hong Kong business for $1.4 billion
Next Post: Chinese private equity firm Tairui acquired stake at Canadian Western Potash for $80 million
Investors Directory 2022
